Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong : SMART 2017-2020
Copyright © 2023 Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc, The Author(s). Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: The aim of this study was to estimate carbapenem resistance in Pseudomonas aeruginosa and Enterobacterales isolated from infected patients in intensive care unit (ICU) and non-ICU hospital wards in Hong Kong.
METHODS: Isolates of Pseudomonas aeruginosa (ICU, n = 35; non-ICU, n = 264) and Enterobacterales (ICU, n = 129; non-ICU, n = 1390) were collected in four Hong Kong hospitals in 2017-2020. Clinical and Laboratory Standards Institute broth microdilution minimum inhibitory concentrations (MICs) were interpreted according to Clinical and Laboratory Standards Institute 2021 M100 breakpoints. β-lactamase genes were identified in imipenem-, imipenem/relebactam-, and ceftolozane/tazobactam-nonsusceptible isolates.
RESULTS: Ceftolozane/tazobactam demonstrated potent in vitro activity against both P. aeruginosa (ICU, 88.6%; non-ICU, 98.5%) and Enterobacterales (96.1%; 97.1%). Percent susceptible values for P. aeruginosa isolates from ICU and non-ICU patients, respectively, were as follows: meropenem (ICU, 74.3%; non-ICU, 84.1%) and imipenem (68.6%; 73.1%). Only 1 of 77 isolates tested for β-lactamase genes carried a carbapenemase (VIM-2). Percent susceptible values for Enterobacterales isolates from ICU and non-ICU patients were as follows: meropenem (100%; 99.4%), ertapenem (100%; 98.0%), and imipenem (88.4%; 88.6%). A total of 62 Enterobacterales isolates were tested for β-lactamase genes. Only three isolates carried a carbapenemase gene; two (both Escherichia coli) were metallo-β-lactamase-positive (both NDM-5), and one (Klebsiella pneumoniae) was OXA-48-like-positive.
CONCLUSIONS: Carbapenem-nonsusceptible isolates of P. aeruginosa were common (>15% of isolates). P. aeruginosa percent susceptible values for ceftolozane/tazobactam (97.3% susceptible overall) were ≥14% higher than those for carbapenems in both ICU and non-ICU isolates. Carbapenemases were rare among both P. aeruginosa (one isolate) and Enterobacterales (three isolates). Most Enterobacterales isolates tested from ICU and non-ICU patients in Hong Kong hospitals in 2017-2020 were susceptible to meropenem and ertapenem (≥98%); imipenem was less active (89% susceptible).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Journal of global antimicrobial resistance - 33(2023) vom: 15. Juni, Seite 260-266 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karlowsky, James A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.06.2023 Date Revised 20.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jgar.2023.04.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355906198 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355906198 | ||
| 003 | DE-627 | ||
| 005 | 20231226065333.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jgar.2023.04.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355906198 | ||
| 035 | |a (NLM)37086892 | ||
| 035 | |a (PII)S2213-7165(23)00071-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karlowsky, James A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong |b SMART 2017-2020 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.06.2023 | ||
| 500 | |a Date Revised 20.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc, The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: The aim of this study was to estimate carbapenem resistance in Pseudomonas aeruginosa and Enterobacterales isolated from infected patients in intensive care unit (ICU) and non-ICU hospital wards in Hong Kong | ||
| 520 | |a METHODS: Isolates of Pseudomonas aeruginosa (ICU, n = 35; non-ICU, n = 264) and Enterobacterales (ICU, n = 129; non-ICU, n = 1390) were collected in four Hong Kong hospitals in 2017-2020. Clinical and Laboratory Standards Institute broth microdilution minimum inhibitory concentrations (MICs) were interpreted according to Clinical and Laboratory Standards Institute 2021 M100 breakpoints. β-lactamase genes were identified in imipenem-, imipenem/relebactam-, and ceftolozane/tazobactam-nonsusceptible isolates | ||
| 520 | |a RESULTS: Ceftolozane/tazobactam demonstrated potent in vitro activity against both P. aeruginosa (ICU, 88.6%; non-ICU, 98.5%) and Enterobacterales (96.1%; 97.1%). Percent susceptible values for P. aeruginosa isolates from ICU and non-ICU patients, respectively, were as follows: meropenem (ICU, 74.3%; non-ICU, 84.1%) and imipenem (68.6%; 73.1%). Only 1 of 77 isolates tested for β-lactamase genes carried a carbapenemase (VIM-2). Percent susceptible values for Enterobacterales isolates from ICU and non-ICU patients were as follows: meropenem (100%; 99.4%), ertapenem (100%; 98.0%), and imipenem (88.4%; 88.6%). A total of 62 Enterobacterales isolates were tested for β-lactamase genes. Only three isolates carried a carbapenemase gene; two (both Escherichia coli) were metallo-β-lactamase-positive (both NDM-5), and one (Klebsiella pneumoniae) was OXA-48-like-positive | ||
| 520 | |a CONCLUSIONS: Carbapenem-nonsusceptible isolates of P. aeruginosa were common (>15% of isolates). P. aeruginosa percent susceptible values for ceftolozane/tazobactam (97.3% susceptible overall) were ≥14% higher than those for carbapenems in both ICU and non-ICU isolates. Carbapenemases were rare among both P. aeruginosa (one isolate) and Enterobacterales (three isolates). Most Enterobacterales isolates tested from ICU and non-ICU patients in Hong Kong hospitals in 2017-2020 were susceptible to meropenem and ertapenem (≥98%); imipenem was less active (89% susceptible) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Carbapenem resistance | |
| 650 | 4 | |a Gram-negative bacilli | |
| 650 | 4 | |a Hong Kong | |
| 650 | 4 | |a ICU | |
| 650 | 4 | |a SMART | |
| 650 | 4 | |a Surveillance | |
| 650 | 7 | |a ceftolozane |2 NLM | |
| 650 | 7 | |a 37A4IES95Q |2 NLM | |
| 650 | 7 | |a Meropenem |2 NLM | |
| 650 | 7 | |a FV9J3JU8B1 |2 NLM | |
| 650 | 7 | |a Ertapenem |2 NLM | |
| 650 | 7 | |a G32F6EID2H |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Imipenem |2 NLM | |
| 650 | 7 | |a 71OTZ9ZE0A |2 NLM | |
| 650 | 7 | |a ceftolozane, tazobactam drug combination |2 NLM | |
| 650 | 7 | |a Tazobactam |2 NLM | |
| 650 | 7 | |a SE10G96M8W |2 NLM | |
| 650 | 7 | |a Carbapenems |2 NLM | |
| 650 | 7 | |a beta-Lactamases |2 NLM | |
| 650 | 7 | |a EC 3.5.2.6 |2 NLM | |
| 700 | 1 | |a Lob, Sibylle H |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Tsz K |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Wei-Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Woo, Patrick C Y |e verfasserin |4 aut | |
| 700 | 1 | |a Seto, Wing Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Ip, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Leung, Stanley W M |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Queenie W-L |e verfasserin |4 aut | |
| 700 | 1 | |a Chau, Rene W Y |e verfasserin |4 aut | |
| 700 | 1 | |a DeRyke, C Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Motyl, Mary R |e verfasserin |4 aut | |
| 700 | 1 | |a Sahm, Daniel F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of global antimicrobial resistance |d 2013 |g 33(2023) vom: 15. Juni, Seite 260-266 |w (DE-627)NLM237523876 |x 2213-7173 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g day:15 |g month:06 |g pages:260-266 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jgar.2023.04.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |b 15 |c 06 |h 260-266 | ||